1

#### AUTISM SPECTRUM DISORDER: A POSSIBLE LINK WITH CHONDROITIN SULFATE

Running head: ASD: a possible link with chondroitin sulfate

Eduardo Listik, M.Sc. Ph.D.<sup>a,b</sup>, Marcia Listik, M.D.<sup>c</sup>, Clarice Listik, M.Sc. M.D.<sup>d</sup>, Leny Toma, Ph.D.<sup>a</sup>

<sup>a</sup> Department of Biochemistry, Universidade Federal de São Paulo. Rua Três de Maio, 100, São Paulo,

SP, Brazil, CEP: 04044-020.

<sup>b</sup> Department of Pathology, University of Alabama at Birmingham, Birmingham AL, USA, 35294

<sup>c</sup> Listik Neuro Serviços Médicos, São Paulo, SP, Brazil. Rua Afonso Celso, 1629 cj. 42, São Paulo, SP, Brazil, CEP: 04119-062.

<sup>c</sup> Department of Neurology, Universidade de São Paulo. Universidade de São Paulo, Center of Movements Disorders, São Paulo SP, Brazil. CEP: 05402-000.

#### **Corresponding author:**

Eduardo Listik, Ph.D.

WTI 330F, 1824 Sixth Avenue South,

Birmingham, AL, 35233.

E-mail: elistik@uabmc.edu

Phone: +1-205-934-6980/1

**Funding:** This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, grant number 2016/18066-6 to LT); and, in part, by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001, including fellowship to EL.

Authors' contributions: ED Prepared all samples, performed data analysis, and drafted the initial manuscript. ML Collected data, carried out the patient care and selection. LT Performed gel electrophoresis. All authors reviewed and revised the manuscript.

Conflict of interest: The authors declare that they have no conflict of interest.

Keywords: Autism, Diagnostics, Developmental disorders, Glycosaminoglycan, Chondroitin sulfate

# 1 ABSTRACT

2	This study aimed to determine discrepancies in the urinary glycosaminoglycan profiles
3	of autism spectrum disorder (ASD) patients (n=9) when compared with those from
4	healthy volunteers (HVs, n=3). The guardians and/or educators for each participant also
5	returned a validated Autism Behavior Checklist (ABC). The urinary chondroitin sulfate
6	(CS) concentration was 46.1% lower in the ASD group than in the HV group. The ABC
7	score and the urinary CS concentration were negatively correlated (Spearman's $\rho{=}{-}$
8	0.2635), indicating that as the severity of the clinical aspect of this disorder increased,
9	the urinary CS concentration decreased. These results suggest that low CS
10	concentrations in the urine may be associated with ASD, and could be measured using a
11	fast and low-cost method for diagnostics.

### 12 INTRODUCTION

Autism spectrum disorder (ASD) are characterized by a lack of social interaction
and impaired verbal and non-verbal communication and can be diagnosed as early as
three years of age (Park et al., 2016).

16 Over the last two decades, ASD diagnoses have steadily increased (Fisch, 2012). 17 Some specialists have argued that this increase has been due to an expansion of the 18 diagnostic criteria and increased social awareness; however, newly diagnosed patients 19 appear to have similar profiles as those diagnosed using previous assessments, and the 20 new criteria do not seem to have influenced these results (Baio et al., 2018; Graf, Miller, 21 Epstein, & Rapin, 2017). The diagnosis of ASD is observational and based on the 22 patient's behavior, although some biomarkers have been proposed (Galiana-Simal, 23 Munoz-Martinez, Calero-Bueno, Vela-Romero, & Beato-Fernandez, 2018).

24 Glycosaminoglycans (GAGs) are complex polysaccharides, composed of 25 repeating disaccharide units. The composition of these units and their linking patterns 26 result in the formation of distinct GAGs, such as chondroitin sulfate (CS), dermatan 27 sulfate (DS) and heparan sulfate (HS) (Gandhi & Mancera, 2008). GAGs may conjugate 28 with proteins, known as proteoglycans, and are essential for embryogenesis and 29 neuronal migration during development. CS proteoglycan mutations may be associated 30 with schizophrenia and bipolar disorder (Couchman, 2010; Iozzo & Schaefer, 2015; 31 Maeda, 2015; Muhleisen et al., 2012; Nakato & Li, 2016; Turner & Grose, 2010). 32 Additionally, excreted GAGs in the urine may be used to diagnose 33 mucopolysaccharidoses (MPS) (Coutinho, Lacerda, & Alves, 2012). Recently, the 34 genes associated with glycan synthesis have been thought to play a role in the 35 development of ASD (Dwyer & Esko, 2016; Endreffy, Bjorklund, Dicso, Urbina, & 36 Endreffy, 2016). Therefore, this study aimed to assess whether the concentrations of

4

GAGs in the urine of ASD patients can be used to facilitate the diagnosis of ASD,
potentially resulting in a better understanding of the ASD pathophysiology and possible
therapeutic targets.

### 40 **METHODS**

### 41 Standard protocol approvals, registrations, and patient consents

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Ethics Committee of Research (n° 14667219.0.0000.5505) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent/assent was obtained from all participants or their guardians.

#### 47 Patients and clinical assessments

48 A pediatric neurologist assessed patients with behavioral or communication 49 difficulties for the evaluation of a possible ASD diagnosis. Exclusion criteria were as 50 follows: younger than 2 years; older than 8 years; neurological lesions; mental 51 deficiency; and other diseases. Patients were also excluded if additional cases of ASD or 52 consanguinity were detected in their family histories. The same exclusion criteria were 53 applied to the healthy volunteers (HVs). The guardians and/or educators for all 54 participants were asked to respond to an electronic version of the validated Autism 55 Behavior Checklist (ABC), which is often used for its ability to identify children with 56 autism. (Marteleto & Pedromonico, 2005) Both total scores and sub-scores were 57 calculated. The sub-scores included: sensory stimulus (SS), use of body and objects 58 (BO), language (LG), and personal-social development (PS). All participants had a 59 urine sample collected, which was stored at -20 °C until processing.

#### 60 Glycosaminoglycan analysis

5

Urine samples were centrifuged at 5,000 rpm for 10 min, 4 mL of the
supernatant were concentrated, using Amicon<sup>®</sup> Ultra centrifugal filters with a molecular
weight cut-off of 3 kDa (Millipore, Massachusetts, USA), and the concentrate was
desalted using 10 mM NaCl (Sun et al., 2015).

65 Concentrated samples were applied to 0.6% agarose slabs, in diaminopropane-66 acetate, 0.05 M (pH 9.0) buffer, and the GAGs were electrophoretically separated at 100 67 V for 60 min (Dietrich & Dietrich, 1976; Jaques, Ballieux, Dietrich, & Kavanagh, 68 1968). Gels were maintained in cetyltrimethylammonium bromide at 0.2% for 1 h and 69 dehydrated completely before being stained with a solution of 0.1% toluidine blue, 1% 70 acetic acid and 50% ethanol for 20 min. The excess dye was removed with quick 71 washes of a destaining solution containing 1% acetic acid and 50% ethanol. The GAG 72 bands were densitometrically quantified and compared with an HS/DS/CS standard to 73 calculate the GAG concentrations in the urine.

#### 74 Data analysis

GAG concentrations and ABC scores were compared between the HV and ASD groups using a Mann-Whitney test, with p < 0.05 representing a significant difference. The two variables were also examined for a possible correlation using Spearman's rankorder correlation test. Variables were screened for outliers using the robust regression and outlier removal test (ROUT's test).

80

#### 0 **Data availability Statement**

81 All data associated with this study are available from the corresponding author,82 upon reasonable request.

#### 83 **RESULTS**

6

This study included 12 participants, nine who were diagnosed with ASD and three HVs. One ASD patient was excluded based on the ROUT's test results for the ABC scores, and one HV was excluded due to sample deterioration. The sample descriptors are summarized in Table 1.

88 Our data revealed that the ABC scores for the ASD patients ( $63.5 \pm 23.4$ ) were 89 significantly higher than those for the HVs ( $5.0 \pm 2.8$ ), as shown in Figure 1B. The ABC 90 sub-scores revealed that ASD patients received higher scores for all investigated 91 parameters, except for the relationship (RE) category (Figure 1B). The gel 92 electrophoresis for the assessment of GAG concentrations in the urine showed the 93 prevalence of CS, small signs of HS and none DS (Figure 1A) A significant reduction 94 (p = 0.04) of 46.1% in the CS concentrations was observed in the urine of ASD patients 95 compared with the urine of HV patients. Whereas ASD patients had a mean CS 96 concentration of 9.44  $\pm$  5.75 mg/L, HVs had a considerably higher mean concentration 97 of  $17.51 \pm 4.04$  mg/L (Figure 1C).

Although a larger sample size would be necessary to estimate a precise correlation between the two examined variables (i.e., ABC score *vs.* CS concentration in urine), we observe that ABC scores for ASD patients were negatively correlated (Spearman's  $\rho = -0.2635$ ) with the measured GAG concentrations in the urine, which could indicate that lower levels of CS in the urine may be associated with worse ASD clinical diagnoses.

### 104 **DISCUSSION**

As previously mentioned, GAGs have been used to monitor MPS. During these pathologies, CS, DS, HS or keratan sulfate (KS) can be observed in patient urine samples, depending on the MPS (Coutinho et al., 2012). However, we discovered that ASD patients display lower urinary CS concentrations for reasons that remain unknown.

7

109 There is no corroborating evidence in the literature that would explain the lower 110 CS concentrations observed in the urine samples from ASD patients. The deletion of 111 *EXT1*, *GPC5*, *GPC6*, and mutation of *HS3ST5* and *SGSH*, appear to be associated with 112 ASD (Dwyer & Esko, 2016). These genes participate in HS synthesis, sulfation, 113 degradation, or HS proteoglycan synthesis. In addition, the deletion of *B3GALT6*, a 114 gene that affects both HS and CS synthesis, also appears to be implicated with ASD 115 (van der Zwaag et al., 2009).

116 The detection of GAGs in the urine may not be appropriate for the detection of 117 HS in these samples, as this GAGs was hardly detectable either in patients with ASD or 118 HVs urines; however, because the glycan balance may be altered in patients with ASD, 119 these alterations can be verified based on the CS concentrations, which revealed 120 significant discrepancies in this pilot study. A larger sample may establish whether 121 urinary CS concentrations can be utilized as a biomarker for ASD and help shed light on 122 the still unknown ASD pathophysiology, and this is a clear limitation of this study. In 123 addition, more studies with HS or specific proteoglycans in the blood or other samples 124 may also increase our understanding of ASD pathophysiology.

In this pilot study, we were able to infer that ASD patients may excrete less CSin the urine, which can be assessed using a fast and low-cost analytical method.

#### 127 **REFERENCES**

128 Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., . . .

- 129 Dowling, N. F. (2018). Prevalence of Autism Spectrum Disorder Among
- 130 Children Aged 8 Years Autism and Developmental Disabilities Monitoring
- 131 Network, 11 Sites, United States, 2014. MMWR Surveill Summ, 67(6), 1-23.
- 132 doi:10.15585/mmwr.ss6706a1

133	Couchman, J. R.	(2010).	Transmembrar	e signaling pi	roteoglycans.	Annu Rev Cell Dev
		· · ·		<i>4 1 1 1 1</i>		

- 134 *Biol*, 26, 89-114. doi:10.1146/annurev-cellbio-100109-104126
- 135 Coutinho, M. F., Lacerda, L., & Alves, S. (2012). Glycosaminoglycan storage disorders:
- 136 a review. *Biochem Res Int, 2012*, 471325. doi:10.1155/2012/471325
- 137 Dietrich, C. P., & Dietrich, S. M. (1976). Electrophoretic behaviour of acidic
- 138 mucopolysaccharides in diamine buffers. Anal Biochem, 70(2), 645-647.
- 139 Retrieved from <u>http://www.ncbi.nlm.nih.gov/pubmed/131498</u>
- 140 Dwyer, C. A., & Esko, J. D. (2016). Glycan susceptibility factors in autism spectrum
- 141 disorders. *Mol Aspects Med*, 51, 104-114. doi:10.1016/j.mam.2016.07.001
- 142 Endreffy, I., Bjorklund, G., Dicso, F., Urbina, M. A., & Endreffy, E. (2016). Acid
- glycosaminoglycan (aGAG) excretion is increased in children with autism
  spectrum disorder, and it can be controlled by diet. *Metab Brain Dis*, *31*(2), 273-
- 145 278. doi:10.1007/s11011-015-9745-2
- 146 Fisch, G. S. (2012). Nosology and epidemiology in autism: classification counts. Am J
- 147 Med Genet C Semin Med Genet, 160C(2), 91-103. doi:10.1002/ajmg.c.31325
- 148 Galiana-Simal, A., Munoz-Martinez, V., Calero-Bueno, P., Vela-Romero, M., & Beato-
- 149 Fernandez, L. (2018). Towards a future molecular diagnosis of autism: Recent
- advances in biomarkers research from saliva samples. Int J Dev Neurosci, 67, 1-
- 151 5. doi:10.1016/j.ijdevneu.2018.03.004
- Gandhi, N. S., & Mancera, R. L. (2008). The structure of glycosaminoglycans and their
  interactions with proteins. *Chem Biol Drug Des*, 72(6), 455-482.
  doi:10.1111/j.1747-0285.2008.00741.x

155	Graf, W. D., Miller, G., Epstein, L. G., & Rapin, I. (2017). The autism "epidemic":
156	Ethical, legal, and social issues in a developmental spectrum disorder.
157	Neurology, 88(14), 1371-1380. doi:10.1212/WNL.000000000003791

- 158 Iozzo, R. V., & Schaefer, L. (2015). Proteoglycan form and function: A comprehensive
- 159 nomenclature of proteoglycans. *Matrix Biol*, 42, 11-55.
  160 doi:10.1016/j.matbio.2015.02.003
- 161 Jaques, L. B., Ballieux, R. E., Dietrich, C. P., & Kavanagh, L. W. (1968). A
- 162 microelectrophoresis method for heparin. Can J Physiol Pharmacol, 46(3), 351-
- 163 360. Retrieved from <u>http://www.ncbi.nlm.nih.gov/pubmed/4177320</u>
- Maeda, N. (2015). Proteoglycans and neuronal migration in the cerebral cortex during
  development and disease. *Front Neurosci*, *9*, 98. doi:10.3389/fnins.2015.00098
- Marteleto, M. R., & Pedromonico, M. R. (2005). Validity of Autism Behavior Checklist
  (ABC): preliminary study. *Braz J Psychiatry*, 27(4), 295-301. doi:/S151644462005000400008
- 169 Muhleisen, T. W., Mattheisen, M., Strohmaier, J., Degenhardt, F., Priebe, L., Schultz,
- C. C., . . . Cichon, S. (2012). Association between schizophrenia and common
  variation in neurocan (NCAN), a genetic risk factor for bipolar disorder. *Schizophr Res, 138*(1), 69-73. doi:10.1016/j.schres.2012.03.007
- 173 Nakato, H., & Li, J. P. (2016). Functions of Heparan Sulfate Proteoglycans in
  174 Development: Insights From Drosophila Models. *Int Rev Cell Mol Biol*, 325,
- 175 275-293. doi:10.1016/bs.ircmb.2016.02.008

176	Park. H. R.	. Lee. J. M.	. Moon. H	. E., Lee.	D. S.,	Kim. B	. N.	Kim. J.,	. Paek. S. H.
1,0		,,	,,		2. ~.,	,,			

- 177 (2016). A Short Review on the Current Understanding of Autism Spectrum
- 178 Disorders. *Exp Neurobiol*, 25(1), 1-13. doi:10.5607/en.2016.25.1.1
- 179 Sun, X., Li, L., Overdier, K. H., Ammons, L. A., Douglas, I. S., Burlew, C. C., . . .
- 180 Linhardt, R. J. (2015). Analysis of Total Human Urinary Glycosaminoglycan
- 181 Disaccharides by Liquid Chromatography-Tandem Mass Spectrometry. Anal
- 182 *Chem*, 87(12), 6220-6227. doi:10.1021/acs.analchem.5b00913
- 183 Turner, N., & Grose, R. (2010). Fibroblast growth factor signalling: from development
  184 to cancer. *Nat Rev Cancer*, *10*(2), 116-129. doi:10.1038/nrc2780
- 185 van der Zwaag, B., Franke, L., Poot, M., Hochstenbach, R., Spierenburg, H. A.,
- 186 Vorstman, J. A., . . . Staal, W. G. (2009). Gene-network analysis identifies
- 187 susceptibility genes related to glycobiology in autism. *PLoS One*, 4(5), e5324.
- 188 doi:10.1371/journal.pone.0005324

# 189 **TABLES**

190 Table 1. Sample descriptors for ASD patients and HVs. The sample size, mean age,

- 191 distribution of sex, and ABC sub-scores and total score are shown for each group. The
- 192 number of individuals removed from each group is shown in the parentheses.

Descriptor	ASD patients	HV	
Sample size	9 (-1)	3 (-1)	
Mean age	$3.9 \pm 1.1$ years	$8.0 \pm 0.0$ years	
Sex	All male	All male	
Tabaiata	Caucasian (88.9%)	Caucasian (100%)	
Ennicity	Asian (11.1%)		
ABC sensory stimulus (SS)	$8.6 \pm 4.4$	$0.0\pm0.0$	
ABC relationship (RE)	$10.6\pm7.2$	$1.5 \pm 2.1$	
ABC use of body and objects (BO)	$14.5\pm8.4$	$0.0\pm0.0$	
ABC language (LG)	$16.2\pm6.0$	$0.0\pm0.0$	
ABC personal and social development (PS)	$13.7\pm6.0$	$3.5\pm0.7$	
ABC total score	$63.5\pm23.4$	$5.0 \pm 2.8$	

## 194 FIGURE CAPTIONS

195 Figure 1. Discrepancies in the CS concentrations in the urine between ASD patients 196 and HVs. (A) Processed urine samples were analyzed for GAG concentrations using an electrophoretic method, in which CS was prevalent. S1 and S2 are the CS/DS/HS 197 198 standards, A1 - A9 (except A7 which was excluded) are ASD patients, and C2 and C3 199 are HVs. (B) ASD patients displayed significantly higher ABC scores than HVs. All of 200 the sub-scores, except for relationship (RE), were higher in ASD patients than in HVs. 201 The horizontal dotted line at y = 49 indicates the scale cut-off. Other sub-scores 202 abbreviations: sensory stimulus (SS), use of body and objects (BO), language (LG), and 203 personal-social development (PS). (C) The measured CS concentration in the urine of 204 ASD patients is significantly lower than that in HVs. (D) A negative correlation 205 between ABC scores and CS concentration in urine, based on the Spearman's p.

13

# 206 FIGURES

